MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
Form 144 filed for MetLife, Inc. (MET) reports a proposed sale of 64 shares of common stock through Bernstein Institutional Services on 09/19/2025 with an aggregate market value of $5,060.48. The filing states the shares were acquired on 12/17/2019 in a purchase from Bank of America and paid for in cash on 12/19/2019. The issuer has 665,026,054 shares outstanding per the filing. The notice also lists multiple sales by MetLife-related accounts between 06/20/2025 and 07/31/2025, totaling 2,628 shares for gross proceeds of $208,112.38. The filer certifies no undisclosed material adverse information.
MetLife disclosed receipt of an unsolicited mini-tender offer from Potemkin Limited to buy up to 10,000 shares of MetLife common stock at $53.00 per share, which the filing states is about 34.42% below MetLife's closing price of $80.82 on September 12, 2025. The shares subject to the offer equal approximately 0.00002% of MetLife's outstanding common stock as of August 31, 2025. MetLife does not endorse the offer, is not associated with Potemkin, and on September 15, 2025 issued a news release advising shareholders not to tender and explaining that shareholders who already tendered may withdraw prior to the offer's scheduled expiration at 5:00 p.m. ET on October 7, 2025. The news release is attached as Exhibit 99.1 and incorporated by reference.
Robert Glenn Hubbard, a director of MetLife, Inc. (MET), reported an acquisition on 09/09/2025 of 663 shares of MetLife common stock at a price of $79.29 per share. The filing shows the shares were credited through imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning dividend payments that became payable were deferred and converted into additional deferred shares. After this transaction the reporting person beneficially owns 101,151 shares. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact on 09/11/2025.
MetLife director Diana McKenzie reported a small insider acquisition under Form 4. On 09/09/2025 she received 158 shares of MetLife common stock at an imputed price of $79.29 through reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors. After the transaction her beneficial ownership is reported as 22,223 shares held directly. The Form 4 was filed as a single reporting person filing and signed on behalf of the reporting person by an attorney-in-fact on 09/11/2025.
Carla A. Harris, a director of MetLife, Inc. (MET), reported an internal share acquisition on 09/09/2025. The Form 4 shows an imputed reinvestment of dividends under MetLife's Deferred Compensation Plan for Non-Management Directors, resulting in the acquisition of 30 shares at a reported price of $79.29 per share. After this transaction, Ms. Harris beneficially owns 8,514 shares in a direct capacity. The filing was signed by an attorney-in-fact on 09/11/2025.
MetLife director Christian Stephane Mumenthaler reported a small non-derivative purchase of 7 shares of MetLife, Inc. common stock on 09/09/2025 at a price of $79.29 per share. The filing states this purchase was an imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning dividends that became payable were deferred and used to acquire additional deferred shares. After the transaction the reporting person beneficially owns 924 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/11/2025.
Laura J. Hay, a director of MetLife, Inc. (MET) reported a non-derivative acquisition of 26 shares of MetLife common stock executed on 09/09/2025 at a reported price of $79.29 per share. After the transaction she is shown as beneficially owning 3,727 shares directly. The filing states this transaction reflects the imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning shares that became payable were deferred and recorded as additional common stock.
This disclosure is routine for director deferred compensation arrangements and documents a small, internal equity accrual rather than an open-market purchase or sale.
MetLife director William E. Kennard reported an imputed reinvestment of dividends that resulted in the acquisition of 312 shares of MetLife common stock at an implied price of $79.29 per share on 09/09/2025. After this transaction he beneficially owns 43,918 shares, held directly and indirectly, with indirect holdings attributable to shares held in the MetLife Policyholder Trust. The filing notes the acquisition arose from the Deferred Compensation Plan for Non-Management Directors, where payable shares were deferred and reinvested.
MetLife, Inc. (MET) director Jeh C. Johnson reported a small non-derivative acquisition of company stock. The Form 4 shows an imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, resulting in an acquisition of 48 shares on 09/09/2025 at an imputed price of $79.29 per share. Following the transaction, the reporting person beneficially owned 6,838 shares. The filing was signed by an attorney-in-fact on 09/11/2025. The disclosure reflects a routine dividend reinvestment rather than an open-market purchase or exercise of options.
MetLife, Inc. filed an initial ownership report for executive Adrienne Karen O'Neill, who serves as EVP & Chief Accounting Officer. As of the event date of September 2, 2025, the filing states that she has no MetLife securities beneficially owned, shown as zero shares in the non-derivative holdings table and no derivative securities listed.
This Form 3 provides a baseline disclosure of her ownership position as a newly reported officer, confirming that she starts with no reported direct or indirect equity holdings in MetLife common stock or related derivative instruments.